Cautiously Optimistic Analyst Sentiment on Mereo BioPharma Group (MREO) Following Disappointing Phase 4 Data for Setrusumab
On December 30, 2025, TheFly reported that Jefferies downgraded Mereo BioPharma Group plc (NASDAQ:MREO) from ‘Buy’ to ‘Hold’.
Mereo Biopharma Group Plc (MREO)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 15,307,347 | $6,378,572 | 0.08% | |
| 2. | 683 Capital Partners Ari Zweiman | 15,025,000 | $6,260,917 | +209% | 0.27% |
| 3. | EcoR1 Capital Oleg Nodelman | 7,856,466 | $3,273,789 | 0.15% | |
| 4. | Schonfeld Strategic Advisors Ryan Tolkin (Cio) | 6,090,381 | $2,537,860 | +252% | 0.01% |
| 5. | 1,999,500 | $833,192 | +32% | 0.14% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.22 | 60,046 | $253,454.17 | 808,921 | 2024-09-13 | Filing | |
| $4.47 | 28,611 | $127,968.42 | 868,967 | 2024-09-12 | Filing | |
| $4.22 | 10,937 | $46,165.08 | 78,630 | 2024-09-13 | Filing | |
| $4.47 | 5,212 | $23,311.71 | 89,567 | 2024-09-12 | Filing | |
| $4.22 | 20,946 | $88,413.07 | 219,061 | 2024-09-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,159,681 | $899,939 | 0.21% | |
| 2. | 1,763,666 | $735,449 | 0% | |
| 3. | 1,585,214 | $660,559 | 0.11% | |
| 4. | 1,558,931 | $650,074 | 0% | |
| 5. | 1,273,785 | $530,787 | 0% |
News See All
10 Stocks Under $1 That Will Explode
U.S. equity markets are beginning their 2026 journey without taking a major break from existing trends, according to Morgan Stanley CIO and chief U.S.
Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143
Mereo BioPharma Group plc (NASDAQ:MREO) is one of the Best 52-Week Low Penny Stocks to Buy Now. On July 9, Mereo BioPharma Group, along with Ultragenyx Pharmaceutical Inc., announced progress in the ...
10 Best 52-Week Low Penny Stocks to Buy Now
On March 26, Gabelli released its Small Cap Outlook for 2025 and beyond.
Mereo BioPharma Group plc (MREO): A Bull Case Theory
We came across a bullish thesis on Mereo BioPharma Group plc (MREO) on Substack by Jake LaMotta. In this article, we will summarize the bulls’ thesis on MREO.
13 Best Biotech Penny Stocks to Buy According to Hedge Funds
Peter Marks's departure from the FDA has left innovators concerned regarding the current state of the review program at the FDA. Marks had impacts on two key areas.
12 Best Biotech Penny Stocks To Invest In Now
Goldman Sachs has spotlighted an often-overlooked sector poised to benefit from lower borrowing costs: biotechnology stocks.
8 Hot Penny Stocks To Invest In According to Hedge Funds
Financial markets are betting that the Federal Reserve's half-point interest rate cut in September will be followed by slower and smaller moves due to the surge in US job growth.
Mereo BioPharma Group plc (MREO): A Bull Case Theory
We came across a bullish thesis on Mereo BioPharma Group plc (MREO) on Raging Bull Investments’ Substack by Jake LaMotta. In this article we will summarize the bulls’ thesis on MREO.
15 Top Performing European Stocks So Far in 2024
In this piece, we will take a look at the 15 top performing European stocks so far in 2024.
Hedge Fund Resource Center